EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice

Frank H Schaftenaar, Andrea D van Dam, Gerjan de Bruin, Marie A C Depuydt iD, Jill de Mol iD, Jacob Amersfoort, Hidde Douna iD, Menno Meijer iD, Mara J Kröner, Peter J van Santbrink, Mireia N A Bernabé Kleijn, Gijs H M van Puijvelde und 6 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024

DOI: 10.1161/atvbaha.123.319701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von Frank H Schaftenaar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of BioTherapeutics, Leiden Academic Centre for Drug Research, the Netherlands (F.H.S., M.A.C.D., J.d.M., J.A., H.D., M.M., M.J.K., P.J.v.S.,…. Hauptthemen laut MEDLINE: Atherosclerosis, Metabolic Syndrome, Disease Models, Animal, Adipose Tissue, White. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atherosclerosis is the major underlying pathology of cardiovascular disease and is driven by dyslipidemia and inflammation. Inhibition of the immunoproteasome, a proteasome variant that is predominantly expressed by immune cells and plays an important role in antigen presentation, has been shown to have immunosuppressive effects. METHODS: We assessed the effect of ONX-0914, an inhibitor of the immunoproteasomal catalytic subunits LMP7 (proteasome subunit β5i/large multifunctional peptidase 7) and LMP2 (proteasome subunit β1i/large multifunctional peptidase 2), on atherosclerosis and metabolism in LDLr –/– and APOE*3-Leiden.CETP mice. RESULTS: ONX-0914 treatment significantly reduced atherosclerosis, reduced dendritic cell and macrophage levels and their activation, as well as the levels of antigen-experienced T cells during early plaque formation, and Th1 cells in advanced atherosclerosis in young and aged mice in various immune compartments. Additionally, ONX-0914 treatment led to a strong reduction in white adipose tissue mass and adipocyte progenitors, which coincided with neutrophil and macrophage accumulation in white adipose tissue. ONX-0914 reduced intestinal triglyceride uptake and gastric emptying, likely contributing to the reduction in white adipose tissue mass, as ONX-0914 did not increase energy expenditure or reduce total food intake. Concomitant with the reduction in white adipose tissue mass upon ONX-0914 treatment, we observed improvements in markers of metabolic syndrome, including lowered plasma triglyceride levels, insulin levels, and fasting blood glucose. CONCLUSIONS: We propose that immunoproteasomal inhibition reduces 3 major causes underlying cardiovascular disease, dyslipidemia, metabolic syndrome, and inflammation and is a new target in drug development for atherosclerosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisMetabolic SyndromeDisease Models, AnimalAdipose Tissue, WhiteReceptors, LDLProteasome Endopeptidase ComplexMice, Inbred C57BLAnimalsMaleProteasome InhibitorsApolipoprotein E3Aortic DiseasesMacrophagesPlaque, AtheroscleroticDendritic CellsMice, Knockout, ApoEMiceEnergy MetabolismOligopeptides

Stichwörter der Autor:innen

T-lymphocytesatherosclerosisdendritic cellsimmunomodulationinflammationmetabolic syndromeproteasome inhibitors

Substanzen

PR-957Receptors, LDLProteasome Endopeptidase ComplexLMP7 proteinProteasome InhibitorsApolipoprotein E3apolipoprotein E3 (Leidein)Oligopeptides

Autor:innen und Institutionen

  • Division of BioTherapeutics, Leiden Academic Centre for Drug Research, the Netherlands (F.H.S., M.A.C.D., J.d.M., J.A., H.D., M.M., M.J.K., P.J.v.S., M.N.A.B.K., G.H.M.v.P., B.S., A.C.F., I.B., J.K.).
  • Division of Endocrinology, Department of Medicine, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, the Netherlands (A.D.D., P.C.N.R.).
  • Department of Chemical Biology, Leiden Institute of Chemistry, the Netherlands (G.d.B., B.I.F.).

ORCID-Profile: Marie A C Depuydt, Jill de Mol, Hidde Douna, Menno Meijer, Bogdan I Florea, Bram Slütter, Amanda C Foks, Ilze Bot, Patrick C N Rensen, Johan Kuiper

Zitieren

APA

Schaftenaar, F. H., van Dam, A. D., de Bruin, G., Depuydt, M. A. C., de Mol, J., Amersfoort, J., Douna, H., Meijer, M., Kröner, M. J., van Santbrink, P. J., Bernabé Kleijn, M. N. A., van Puijvelde, G. H. M., Florea, B. I., Slütter, B., Foks, A. C., Bot, I., Rensen, P. C. N., & Kuiper, J. (2024). Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.319701

Vancouver

Schaftenaar FH, van Dam AD, de Bruin G, Depuydt MAC, de Mol J, Amersfoort J, et al. Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.123.319701

BibTeX
@article{Schaftenaar2024,
  author = {Schaftenaar, Frank H and van Dam, Andrea D and de Bruin, Gerjan and Depuydt, Marie A C and de Mol, Jill and Amersfoort, Jacob and Douna, Hidde and Meijer, Menno and Kröner, Mara J and van Santbrink, Peter J and Bernabé Kleijn, Mireia N A and van Puijvelde, Gijs H M and Florea, Bogdan I and Slütter, Bram and Foks, Amanda C and Bot, Ilze and Rensen, Patrick C N and Kuiper, Johan},
  title = {Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  doi = {10.1161/atvbaha.123.319701}
}
Kostenlos starten →